|
|
|
| Effect of Cetuximab combined with Different Chemotherapy Regimens on Survival and Adverse Reactions of Patients with Advanced Rectal Cancer |
| ZHU Zhou, CHEN Rixin, QIN Jianing, et al |
| Liuzhou People's Hospital, Guangxi Liuzhou 545000, China |
|
|
|
|
Abstract Objective: To investigate the effect of cetuximab combined with different chemotherapy regimens in patients with advanced rectal cancer. Methods: 60 patients with advanced rectal cancer in our hospital were enrolled according to the random number table. 30 patients in FOLFIRI group received cetuximab plus FOLFIRI chemotherapy, and 30 patients in FOLFOX4 group received cetuximab plus FOLFOX4 chemotherapy Treatment. Observe and compare clinical treatment effects and serum epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), insulin-like growth factor-1 (IGF-1) levels, T lymphocyte subsets (CD3+) (CD4+) level changes before and after treatment, and statistical changes in the quality of life (independence, physiological function, psychological function, social relationship) scores before and after treatment, and the incidence and survival of adverse reactions. Results: The disease control rate was 66.67% (20/30) in FOLFOX4 group and 56.67% (17/30) in FOLFIRI group. There was no significant difference between the two groups (P > 0.05). The level of serum EGFR in two groups was significantly lower than that before treatment (P < 0.05), but there was no significant difference between the two groups (P > 0.05). The levels of serum VEGF and IGF-1 in FOLFOX4 group were lower than those in FOLFIRI group after 2 cycles of treatment (P < 0.05); there was no significant difference in the incidence of liver dysfunction between the two groups (P > 0.05); the incidence of leukopenia in FOLFOX4 group was 3.33% (1/30), and the incidence of nausea and vomiting was 3.33% (1/30). The incidence of diarrhea was 10.00% (3/30), the incidence of thrombocytopenia was 6.67% (2/30), which was lower than that of FOLFIRI group (P < 0.05); the median progression-free survival time of FOLFOX4 group was 11.2 months, and the median overall survival time was 28.90 months, which was higher than that of FOLFIRI group (7.03 months, 19.90 months) (P < 0.05). Conclusion: Cetuximab combined with oxaliplatin-based FOLFOX4 chemotherapy regimen for advanced rectal cancer patients is effective and safe. It can reduce serum levels of vascular endothelial growth factor and insulin-like growth factor-1 and prolong the survival time of patients.
|
|
|
|
|
|
[1] 李慧,江旭,杨朝爱,等.动脉微泵灌注奥沙利铂治疗结直肠癌术后肝转移[J].中国介入影像与治疗学,2017,14(8):455~459.
[2] Jonker D J,Karapetis C S,Harbison C,et al.Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer[J].Br Cancer,2014,110(3):648~655.
[3] 张婷婷,苏丹,李娟,等.西妥昔单抗联合化疗治疗转移性结直肠癌的临床疗效观察[J].中华胃肠外科杂志,2015,18(6):584~588.
[4] 李寿杰,陈高峰,付啸风.艾迪注射液联合FOLFOX4方案化疗治疗结肠癌的临床疗效观察[J].吉林医学,2016,37(8):2023~2024.
[5] 王福玲.世界医学会《赫尔辛基宣言》-涉及人类受试者的医学研究的伦理原则[J].中国医学伦理学,2016,29(3):544~546.
[6] 袁泉良,韩柯,任东方,等.血清VEGF和CRP表达在结直肠癌病人中的临床意义和诊断价值[J].中国卫生检验杂志,2015,25(6):838~841.
[7] 殷华芳,王琼,孙霞,等.扶正抑癌方对结肠癌根治术后患者血清IGF-1、EGF、TK1、CRP、CA199及CD4+淋巴细胞亚群水平的影响[J].海南医学院学报,2016,22(12):1236~1239.
[8] 宋均飞,刘弋.EGFR、HER2在结直肠癌患者血清与组织中的表达及其临床意义分析[J].中华疾病控制杂志,2016,20(4):403~407.
[9] 林丹丹,张一桥,陈能,等.卡培他滨联合奥沙利铂对比氟尿嘧啶联合奥沙利铂治疗结直肠癌疗效与安全性的Meta分析[J].中国肿瘤,2016,25(11):927~932. |
|
|
|
2019, Vol. 25 
